Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
- PMID: 10229227
- DOI: 10.1038/8394
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
Abstract
Combination therapy for HIV-1 infection can reduce plasma virus to undetectable levels, indicating that prolonged treatment might eradicate the infection. However, HIV-1 can persist in a latent form in resting CD4+ T cells. We measured the decay rate of this latent reservoir in 34 treated adults whose plasma virus levels were undetectable. The mean half-life of the latent reservoir was very long (43.9 months). If the latent reservoir consists of only 1 x 10(5) cells, eradication could take as long as 60 years. Thus, latent infection of resting CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective anti-retroviral therapy.
Comment in
-
HIV-1 and HAART: a time to cure, a time to kill.Nat Med. 1999 Jun;5(6):609-11. doi: 10.1038/9452. Nat Med. 1999. PMID: 10371490 No abstract available.
-
The QUEST trial, a paradigm of HIV collaborative research.Nat Med. 2000 Nov;6(11):1194. doi: 10.1038/81251. Nat Med. 2000. PMID: 11062508 No abstract available.
Similar articles
-
The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.Nat Med. 2000 Jan;6(1):82-5. doi: 10.1038/71577. Nat Med. 2000. PMID: 10613829
-
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.N Engl J Med. 1999 May 27;340(21):1605-13. doi: 10.1056/NEJM199905273402101. N Engl J Med. 1999. PMID: 10341272 Clinical Trial.
-
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.Annu Rev Immunol. 2000;18:665-708. doi: 10.1146/annurev.immunol.18.1.665. Annu Rev Immunol. 2000. PMID: 10837072 Review.
-
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.Nature. 1997 May 8;387(6629):183-8. doi: 10.1038/387183a0. Nature. 1997. PMID: 9144289
-
Inducible HIV RNA transcription assays to measure HIV persistence: pros and cons of a compromise.Retrovirology. 2018 Jan 17;15(1):9. doi: 10.1186/s12977-017-0385-y. Retrovirology. 2018. PMID: 29343255 Free PMC article. Review.
Cited by
-
STING Ligand-Mediated Priming of Functional CD8+ T Cells Specific for HIV-1-Protective Epitopes from Naive T Cells.J Virol. 2021 Jul 26;95(16):e0069921. doi: 10.1128/JVI.00699-21. Epub 2021 Jul 26. J Virol. 2021. PMID: 34076478 Free PMC article.
-
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.J Clin Invest. 2015 May;125(5):1901-12. doi: 10.1172/JCI80142. Epub 2015 Mar 30. J Clin Invest. 2015. PMID: 25822022 Free PMC article.
-
HIV-infected cells are frequently clonally expanded after prolonged antiretroviral therapy: implications for HIV persistence.J Virus Erad. 2015 Oct 1;1(4):237-44. doi: 10.1016/S2055-6640(20)30930-4. J Virus Erad. 2015. PMID: 27482422 Free PMC article. Review.
-
Early exposure to broadly neutralizing antibodies may trigger a dynamical switch from progressive disease to lasting control of SHIV infection.PLoS Comput Biol. 2020 Aug 20;16(8):e1008064. doi: 10.1371/journal.pcbi.1008064. eCollection 2020 Aug. PLoS Comput Biol. 2020. PMID: 32817614 Free PMC article.
-
G-Quadruplex DNA and Other Non-Canonical B-Form DNA Motifs Influence Productive and Latent HIV-1 Integration and Reactivation Potential.Viruses. 2022 Nov 11;14(11):2494. doi: 10.3390/v14112494. Viruses. 2022. PMID: 36423103 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
